| 2.76 -0.61 (-18.1%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.45  |
1-year : | 6.85 |
| Resists | First : | 4.67 |
Second : | 5.86 |
| Pivot price | 4.42 |
|||
| Supports | First : | 2.74 |
Second : | 2.27 |
| MAs | MA(5) : | 3.45 |
MA(20) : | 4.64 |
| MA(100) : | 6.34 |
MA(250) : | 13.69 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 3.7 |
| RSI | RSI(14): 14 |
|||
| 52-week | High : | 33.68 | Low : | 2.74 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ UPB ] has closed below the lower bollinger band by 4.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 82.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.38 - 3.41 | 3.41 - 3.43 |
| Low: | 2.68 - 2.72 | 2.72 - 2.74 |
| Close: | 2.72 - 2.78 | 2.78 - 2.81 |
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Thu, 15 Oct 2026
Upstream Bio (UPB) Slides 2.63% to $3.33 as Shares Drift Toward Lower Support - PCR Spike - https://www.siam.in/
Thu, 17 Sep 2026
Upstream Bio (UPB) exec offloads shares to cover taxes - Stock Titan
Tue, 08 Sep 2026
Upstream Bio (NasdaqGS:UPB) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 01 Sep 2026
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - GlobeNewswire
Wed, 19 Aug 2026
Upstream Bio Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tue, 11 Aug 2026
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 4.281e+007 (%) |
| Held by Institutions | 14.7 (%) |
| Shares Short | 4,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6978e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 480.9 % |
| Return on Equity (ttm) | -30.3 % |
| Qtrly Rev. Growth | 3.16e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -136 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 4.51e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|